Participation of members from Oslo Diabetes Research Centre at EASD 2017

Several abstracts by  members from  Oslo Diabetes Research Centre have been accepted for presentation at the annual EASD in Lisboa September 11-15, 2017:

1. Time-trends in incidence and prevalence of type 2 diabetes patients requiring glucose-lowering treatment from 2007-2015: nationwide data from Norway and Sweden. D. Nathanson, J. Bodegard, A. Norhammar, K.I. Birkeland, T. Nyström, M. Thuresson, J.W. Eriksson, H.L. Gulseth

2. Type 2 diabetes in general practice in Norway, status and time trends. Å. Bakke, J.G. Cooper, G. Thue, I. Dalen, S. Skeie, S. Carlsen, E.R. Oord, K.F. Løvaas, T.V. Madsen, A.T. Tran, A.K. Jenum, T.J. Berg, B. Gjelsvik, T. Claudi, S. Sandberg

3. Plasma soluble leptin receptor predicts insulin sensitivity in humans. C. Sommer, S. Lee, H.L. Gulseth, J. Jensen, C.A. Drevon, K.I. Birkeland

4. Hospitalisation for heart failure and death in new users of SGLT-2 inhibitors in patients with and without cardiovascular disease: the CVD-REAL study. M.A. Cavender, A. Norhammar, K.I. Birkeland, M.E. Jørgensen, J.P. Wilding, K. Khunti, A.Z. Fu, J. Bodegård, B. Blak, E.T. Wittbrodt, M. Thuresson, P. Fenici, N. Hammar, M. Kosiborod, on behalf of the CVDREAL Investigators and StudyGroup

5. Total events of hospitalisation for heart failure in new users of SGLT-2 inhibitors: real world data from 5 countries and more than 298,000 patients: the CVD-REAL study. M. Kosiborod, M.A. Cavender, A.Z. Fu, A. Norhammar, K.I. Birkeland, M. Jørgensen, R.W. Holl, N. Hammar, E.T. Wittbrodt, J. Bodegård, M. Scheerer, M. Thuresson, P. Fenici, on behalf of the CVD-REAL Investigators and StudyGroup

6. Dapagliflozin is associated with lower risk of major adverse cardiovascular events compared to DPP-4i in type 2 diabetes patients. Results from CVD-REAL Nordic. A. Norhammar, M. Kosiborod, H. Gulseth, J.W. Eriksson, P. Fenici, D. Nathanson, J. Bodegard, M. Thuresson, T. Nyström, K.I. Birkeland

7. Dapagliflozin compared to DPP4i treatment is associated with lower risk of kidney disease, heart failure and all-cause death: CVD-REAL Nordic. J.W. Eriksson, A. Norhammar, J. Bodegard, M. Thuresson, P. Fenici, D. Nathanson, M. Kosiborod, H.L. Gulseth, T. Nyström, K.I. Birkeland

8. Second line treatment after metformin monotherapy of type 2 diabetes in a real life setting 2006 to 2015: nationwide data comparison between Denmark, Norway and Sweden. F. Persson, J. Bodegard, T. Nyström, D. Nathanson, M. Thuresson, M. Linnemann Jensen, M.E. Jørgensen, K.I. Birkeland, H.L. Gulseth, A. Norhammar, J.W. Eriksson

9. Life years lost and cardiovascular risk in type 2 diabetes patients requiring glucoselowering treatment 2008-2015: nationwide data from Norway and Sweden. H.L. Gulseth, J. Bodegard, A. Norhammar, D. Nathanson, M. Thuresson, K.I. Birkeland, J.W. Eriksson, T. Nyström

10. Indexes of body fat, but not BMI, are associated with cardiovascular (CV) mortality in subjects with diabetes (DM) during 17 year follow-up in the Norwegian HUNT2 study. A.P. Ofstad, C. Sommer, K.I. Birkeland, M.R. Bjørgaas, J.M. Gran, O.E. Johansen, H.L. Gulseth

11. Enteroviruses in the pancreas of live adult patients with newly diagnosed type 1 diabetes. Results from the DiViD study. L. Krogvold, A. Genoni, A. Puggioni, D. Campani, S. Richardson, B. Edwin, T. Buanes, K. Dahl-Jørgensen, A. Toniolo

12. Pandemic influenza diagnosis and subsequent risk of type 1 diabetes. P.L.D. Ruiz, G. Tapia, I.J. Bakken, S.E. Håberg, H.L. Gulseth, L.C. Stene

Lower risk of heart failure, cardiovascular disease and overall mortality in patients with type 2 diabetes following initiation of SGLT2 inhibitors

The article Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis, recently published in Lancet Diabetes & Endocrinology,  shows that the use of sodium-glucose co-transporter-2 (SGLT2) inhibitors in normal clinical practice is associated with lower risk of heart failure, cardiovascular disease and overall mortality, compared with the use of other glucose-lowering drugs used for type 2 diabetes.

Read More »

Annual Report 2016

The 2016 annual report shows a striking and steady increase in the number and quality of publications from clinical and basic science. Another striking trend is the increased international collaboration. Several of our researchers also play prominent roles in national and international organizations promoting education, research and improved care for patients with diabetes. 

Please click here to read Oslo Diabetes Research Centre’s Annual Report 2016.